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was found in 21 patients (67.8%) and stable disease (SD) was 
observed in 10 cases (32.2%). SD after chemotherapy was 
reported more often in patients qualified to high expression 
of βT-II, whereas PR in the group of low protein expression 
(p=0.004). The increase in Histoscore (HS) parameter 
obtained from the computer image analysis was correlated 
with the observed lower regression of the tumor (r=–0.43, 
p=0.017). In patients with SD effect observed after induction 
chemotherapy the mean value of HS was 109.5 whereas in 
the PR group the mean value of HS was 28.34. No correlation 
between the response to radiotherapy and βT-II expression 
was found (p=0.92). The difference in 1-year OS and PFS was 
not shown for the patients from neither the high or low βT-II 
expression (OS 75% vs 63%; p=0.69, PFS 63% vs 58%; p=0.69). 
Conclusions: The βT-II protein expression level in tumor 
tissue is a predictive factor for clinical response to taxane-
based neoadjuvant chemotherapy in LASHNC. In the case of 
high βT-II expression the most probable effect of 
chemotherapy is tumor stabilization. Low βT-II expression 
level may be a parameter used to select the patients with 
prognozed good response to TPF chemotherapy. In these 
patients realization of radiotherapy may be easier without 
the risk of delayed definitive treatment.  
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Purpose/Objective: To investigate effects of the epidermal 
growth factor receptor (EGFR) polymorphisms on survival for 
advanced oral cancer patients. 
Materials and Methods: A total of 156 patients with 
advanced oral cancer were treated with a uniform induction 
chemotherapy (Methotrexate 30 mg/m2 D1, Epirubicin 30 
mg/m2 D1, alternating with Mitomycin-C 4 mg/m2 D8, 
Oncovin 1 mg/m2 D8, Cisplatin 25 mg/m2 D8, Leucovorin 120 
mg/m2 D8, 5-fluorouracil 1000 mg/m2 D8, and Bleomycin 10 
mg/m2 D8) for 8-12 weeks followed by local treatment 
(surgery/radiotherapy). Most patients (97.5%) belonged to 
stage IV and 70% presented with unresectable tumor. DNA 
extracted from peripheral blood cells of each patient were 
used for genotyping. Four EGFR polymorphisms, codon 497 
(R497K), CA simple sequence repeat 1 (CA-SSR1) in intron 
one, and two single nucleotide polymorphisms in the 
promoter region (-216 G to T and -191 C to A) were 
examined. Overall survival (OS) and locoregional failure-free 
survival (LRFFS) according to EGFR polymorphisms were 
analyzed. 
Results: The frequencies of the R/R, R/K, and K/K genotypes 
for R497K polymorphism were 26.3%, 48.7%, and 25.0%, 
respectively. The G/G, G/T, and T/T genotypes distribution 
for the -216 G to T polymorphism showed 91.0%, 7.7%, and 
1.3%, respectively. Most patients (86.5%) belong to a longer 
CA repeats (>35 repeat) genotype. For the -191 C to A 
polymorphism, 100% patients were C/C type. Patients with 
heterozygosity of EGFR codon 497 (Arg/Lys) showed better 
survivals (5-year OS=34.9% vs. 23.1%, P=0.1545; 5-year 
LRFFS=46.2% vs. 24.9%, P=0.0663) than those of homozygosity 
(Arg/Arg or Lys/Lys). Better survivals were observed in 
patients with variant SNP -216 G/G genotype than those of -
216 G/T or T/T genotypes (5-year OS=29.4% vs. 11.0%, 
P=0.0661; 5-year LRFFS=36.9% vs. 11.2%, P=0.0179). 
Combined both R497K and -216 G to T polymorphisms have 
more significant effects on OS (P=0.014) and LRFFS (P=0.010). 
The lengths of CA-SSR1 repeats did not affect survival. 
Conclusions: Combination of the R497K and -216 G to T 
polymorphisms of the EGFR is a significant prognostic factor 
in predicting survival for patient with advanced oral cancer. 
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Purpose/Objective: The aim of the study was to report the 
long-term clinical outcomes of nasopharynx cancer patients 
treated with cisplatin based concurrent chemoradiation 
(RCT). 
Materials and Methods: Patients with nasopharynx tumor 
(UICC Stage II-IV) treated with definitive RCT or neoadjuvant 
chemotherapy (NACT: Cisplatin + 5-Fluorouracil (CF) or 
Docetaxel + Cisplatin + 5-Fluorouracil (DCF)) followed by RCT 
from January 2006 to January 2014 were included in the 
analysis. According to a dose-escalation protocol, a total of 
67.5-70.5 Gy in 30 fractions were delivered to primary tumor 
and involved nodes, 60 Gy in 30 fractions to high-risk nodal 
areas, and 55.5 Gy in 30 fractions to low-risk nodal areas. 
Simultaneous integrated boost IMRT/VMAT technique was 
used. Local control and overall survival were estimated by 
the Kaplan-Meier method. 
Results: 26 patients (M/F: 19/7; median age: 55 years; 
range: 30-79 years; UICC stage: II (3 patients), III (8 patients) 
and IV (15 patients)) were treated and analyzed. 3 cycles of 
NACT (CF or DCF) was administered in 21 patients (81%). 15 
patients were treated with IMRT/SIB and 11 with VMAT/SIB. 
Grade 3 or 4 acute toxicities (RTOG score) were: oral 
mucositis (8 patients: 31%); dysphagia (1 patient: 4%); 
dysphonia (2 patients: 8%); hematological suppression (6 
patients: 23%). No Grade 3 or 4 late toxicity (RTOG EORTC 
score) was recorded. The 2- and 5-year local control were 
84% and 60% and 2- and 5-year overall survival were 75% and 
44%, respectively. 
Conclusions: In our experience, a moderately accelerated 
concurrent RCT, even after induction chemotherapy, is 
feasible and well tolerated. Taking into account the 
